Mehmet Samur
Senior Research Scientist
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (20)
Transcription factors and their cofactors are major and selective nononcogene dependencies in multiple myeloma cells. By performing a gain-of-function perturbation screen in human multiple myeloma cell lines, we identified the inhibitor of DNA binding ( ID ) genes as putative suppressors of multiple myeloma cell fitness. Among them, ID2 was found to be downregulated in multiple myeloma patient cells and acted as a tumor suppressor by directly binding and repressing the basic helix-loop-helix factor TCF3, also known as E2A. Lower ID2 expression in multiple myeloma cells conferred a proliferative advantage by increasing TCF3 activity, leading to a dependency on this transcription factor. In contrast, ID2 overexpression reduced TCF3 binding to DNA, which resulted in cell-cycle arrest and a halt in multiple myeloma cell proliferation. The myeloma bone marrow milieu supported this process by further decreasing the expression of ID2 and enhancing TCF3 activity, partly via IL6, revealing a mechanism by which the tumor microenvironment affects multiple myeloma cell behavior. Significance: Multiple myeloma cells exploit the oncogenic and proliferative potential of TCF3 by downregulating the transcriptional regulator ID2, a process facilitated by the bone marrow microenvironment.
Year:
2026
Supplementary Figure S1. Discovery of ID2 as a putative tumor suppressor in MM. Supplementary Figure S2. ID2 expression causes cell cycle arrest in MM cells. Supplementary Figure S3. Induced ID2 expression in MM cells is associated with senescence-like features. Supplementary Figure S4. TCF3 is a highly expressed selective dependency in MM cells. Supplementary Figure S5. Depletion of TCF3 phenocopies effects of ID2 overexpression in MM cells. Supplementary Figure S6. The bone marrow milieu has a role in supporting TCF3 activity in MM.
Year:
2026
Despite significant improvements in survival of patients with multiple myeloma (MM), outcomes remain heterogeneous, and a significant proportion of patients experience suboptimal outcomes. Importantly, traditional prognostic factors based on data from patients treated with older therapies no longer capture prognosis accurately in the contemporary era of novel triplet or quadruplet therapies. Therefore, risk stratification requires refinement in the context of available and investigational treatment options in routine practice and clinical trials, respectively. The current identification of high-risk MM (HRMM) in routine practice is based on the Revised International Staging System, which stratifies patients using a combination of widely available serum biomarkers and chromosomal abnormalities assessed via fluorescence in situ hybridization. In recent years, a substantial body of evidence concerning additional clinical, biological, and molecular/genomic prognostic factors has accumulated, along with new MM risk stratification tools and consensus reports. The International Myeloma Society, along with the International Myeloma Working Group, convened an Expert Panel with the primary aim of revisiting the definition of HRMM and formulating a practical and data-driven consensus definition, based on new evidence from molecular/genomic assays, updated clinical data, and contemporary risk stratification concepts. The Panel proposes the following Consensus Genomic Staging (CGS) of HRMM which relies upon the presence of at least one of these abnormalities: (1) del(17p), with a cutoff of >20% clonal fraction, and/or TP53 mutation; (2) an IgH translocation including t(4;14), t(14;16), or t(14;20) along with 1q+ and/or del(1p32); (3) monoallelic del(1p32) along with 1q+ or biallelic del(1p32); or (4) β2 microglobulin ≥5.5 mg/L with normal creatinine (<1.2 mg/dL).
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Multiple myeloma (MM) is an incurable malignancy of clonally expanded plasma cells shaped by complex interactions with the immune microenvironment. To investigate immune factors driving treatment response and resistance, we conducted multi-omics profiling including CD138 neg single-cell RNA sequencing of 243 bone marrow samples from 102 patients (631,226 cells) and CD138 pos bulk RNA and whole-genome sequencing from 209 samples. Longitudinal analyses revealed that interferon gamma signaling impairs T cell memory after autologous stem cell transplant, while naïve B cell abundance and immunoglobulin diversity correlated with improved progression-free survival (HR = 0.48, p = 2.3e -4 ). At disease progression, MM cells upregulated cancer-testis antigens and immune effector genes, with concurrent B cell depletion, enrichment of myeloid-derived suppressor cell genes in monocytes, and T cell exhaustion. These findings highlight dynamic immune-tumor interactions, identifying naïve B cell reconstitution as a biomarker of durable response, and cancer-testis antigens as potential targets for high-risk disease at progression. Statement of Significance Longitudinal profiling of multiple myeloma and the immune microenvironment revealed dynamic immune-tumor interactions across the disease course. Dysfunctional CD8⁺ T cells limited memory formation post-transplant, while naïve B recovery associated with sustained treatment response. At progression, cancer-testis antigen expression associated with immunosuppression, revealing novel mechanisms of immune escape.
Year:
2025
Supplementary Figure S4. Impact of pharmacological inhibition (ND-630 and ND-646) and ACC1 knockdown on MM cell viability, proliferation, and de novo lipogenesis (DNL) rates in MYC overexpressed MM cells.
Year:
2025
Purpose: In multiple myeloma, tumor cells reprogram metabolic pathways to sustain growth and monoclonal immunoglobulin production. This study examines acetyl-CoA carboxylase 1 ( ACC1 ), the enzyme driving the rate-limiting step in de novo lipogenesis, in multiple myeloma metabolic reprogramming, particularly in c- MYC ( MYC )–driven subtypes. Experimental Design: ACC1 expression was evaluated across multiple myeloma genetic subgroups, focusing on MYC translocations. Functional studies using ACC1 inhibitors and genetic knockdown assessed multiple myeloma cell growth, lipid synthesis, and metabolic homeostasis in vitro and in vivo . The role of MYC overexpression in ACC1 sensitivity was examined, with palmitate rescue experiments. Lipidomic analysis and assessments of endoplasmic reticulum (ER) stress, protein translation, and oxidative damage elucidated underlying mechanisms. Results: ACC1 was overexpressed in MYC -translocated multiple myeloma. Its inhibition or knockdown reduced multiple myeloma cell growth in vitro and in vivo , particularly in MYC- overexpressing cells. ACC1 knockdown suppressed de novo lipid synthesis, partially rescued by palmitate. Lipidomic disruptions increased cholesterol ester desaturation and altered phospholipid ratios, inducing ER stress, impaired translation, protein carbonylation, oxidative damage, and apoptosis. Conclusions: ACC1 is a metabolic vulnerability in MYC -driven multiple myeloma. Inhibiting ACC1 disrupts lipid homeostasis, induces ER stress, and causes oxidative damage, impairing cell survival. Targeting lipid synthesis pathways, especially in MYC -dependent subtypes, offers a promising therapeutic strategy for multiple myeloma.
Year:
2025
To study the heterogeneity of transcriptional and genomic traits that underlie the clinical presentation of untreated Waldenstrom’s Macroglobulinemia (WM), we performed multi-omic studies in 249 treatment-naive patients with WM. For all patients, RNASeq was performed on CD19-selected bone marrow (BM) MYD88 mutated samples as well as 13 paired CD19 + CD27 − and CD19 + CD27 + peripheral blood samples from healthy donors. Whole exome sequencing (WES) was also analyzed on paired tumor and germline DNA for 229 of these patients and DNA methylation status was assessed by enhanced reduced representational bisulfite sequencing (ERRBS) for 32 samples. The ERRBS and transcriptional data identified two distinct cells of origin for WM leading to two independent WM subtypes known as B-cell Like (BCL) and Plasma Cell Like (PCL). A third subtype, Early WM, was observed primarily in smoldering WM and was present in both ERRBS clusters identifying it as a transcriptional state common to early BCL and PCL. We further identified the WM Evolutionary Score (EScore), a gene signature common to all samples that predicted time to first therapy and corresponded with progression to symptomatic WM. Analysis of the EScore revealed a subclone expressing pre-B-cell, T-cell, stem cell and myeloid markers that was confirmed by flow cytometry and detected in early (smoldering) WM with subpopulations persisting with WM evolution. Our findings have important implications for WM pathogenesis. The evolution from the Early WM subtype to either BCL or PCL and EScore explains much of the genomic, transcriptional and clinical heterogeneity of WM including clinical outcomes to primary therapy.
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (43)
Shaji Kumar
Medical College of Wisconsin
Karthik Ramasamy
Cancer Divisional Lead
University of Oxford
Jill Corre
-
Brian Walker
Professor
University of Miami
Steven Treon
Professor
Harvard Medical School
Adam Sperling
Assistant Professor
Stanford University
Manoj Bhasin
Director, Genomics, Proteomics, Bioinformatics and Single cell Biology
Children's Healthcare of Atlanta
Charles B. Epstein
Broad Institute
Ioannis Vlachos
Broad Institute
Massimo Loda
Chair
Weill Cornell Medical College
David Avigan
Vice Chair of Oncology
Dana-Farber Cancer Institute
Anil Aktas Samur
Senior Scientist
Dana-Farber Cancer Institute
Martin Kaiser
Professor of Haematology
The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust
Shirong Liu
Senior Scientist
Dana-Farber Cancer Institute
Samir Parekh
Director, Center of Excellence for Multiple Myeloma
Icahn School of Medicine at Mount Sinai
Robert Orlowski
Florence Maude Thomas Cancer Research Professor
The University of Texas MD Anderson Cancer Center
James Dunford
University of Oxford
Eugenio Morelli
Assistant Professor
Università degli Studi di Torino
jun qi
Assistant Professor
Dana-Farber Cancer Institute
Sagar Lonial
-
Alice Cleynen
Directrice de Recherche CNRS
Université Grenoble Alpes
Ajay K. Nooka
Professor
Emory University
Cirino Botta
Assistant Professor of Hematology
University of Palermo
Mattia D'Agostino
Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino
Ravi Vij
Washington University School of Medicine
Giorgio Inghirami
Professor
Weill Cornell Medical College
Romain Lannes
Whitehead Institute for Biomedical Research
Annamaria Gulla
Group leader
Candiolo Cancer Institute, FPO-IRCCS
Madhav V. Dhodapkar
-
Raphael Szalat
Assistant professor
Boston University
Herve Avet-Loiseau
-
Bruno David Lourenço Paiva
Clinica Universidad de Navarra
Jorge Castillo
Clinical Director, Bing Center for Waldenstrom Macroglobulinemia
Dana-Farber Cancer Institute
Edgar Ernesto Gonzalez Kozlova
Assistant Professor
-
Lawrence Boise
Professor
Emory University
Norma C. Gutiérrez
-
Marc S. Raab
University Hospital Heidelberg
Mani Larijani
Shrum Chair in Biological Mechanisms of Disease & Associate Professor
Simon Fraser University
Daniel W. Sherbenou
Associate Professor
University of Colorado Anschutz Medical Campus
Adam P Cribbs
Group leader in systems biology and MRC Career Development Fellow
-
Jonathan Keats
Director of Bioinformatics / Assistant Professor
Translational Genomics Research Institute
Markus Hansson
Professor
Sahlgrenska universitetssjukhuset
Ari M. Melnick
Director
Josep Carreras Leukaemia Research Institute
Make your next move.
Prepare your application
Review drafts before you send them.